{'fraction_non_alphanumeric': 0.020127118644067795, 'fraction_numerical': 0.00211864406779661, 'mean_word_length': 5.798561151079137, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Haemostasis and Vascular Disease in Dialysis Patients Receiving Erythropoietin Therapy

Despite major advances, particularly over the last 20 years, in the development of renal replacement therapy, many patients with renal failure still have a poor quality of life, and a death rate from myocardial infarction comparable to that in non-uraemic patients with a history of previous myocardial infarction.! Abnormalities in haemostasis determined in part by the underlying disease process, the biochemical, acid-base, and endocrine abnormalities associated with chronic renal failure, and the type of renal replacement therapy undertaken, may be factors having a significant role in the development and progression of vascular disease in these patients. Similarly, therapeutic manipulation of haemostasis may either improve or worsen the incidence of vascular thrombotic events. In this respect, the introduction and use of erythropoietin (EPa) in